If playback doesn't begin shortly, try restarting your device.
•
You're signed out
Videos you watch may be added to the TV's watch history and influence TV recommendations. To avoid this, cancel and sign in to YouTube on your computer.
CancelConfirm
Share
An error occurred while retrieving sharing information. Please try again later.
932 views • Nov 21, 2023 • #PancreaticCancer #immunotherapy #CancerResearch
Show less
Renovaro Biosciences CEO Dr Mark Dybul joined Steve Darling from Proactive to share news about the significant progress the company is poised to make following the signing of a definitive agreement to merge with GEDiCube, a UK-based medical AI company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. GEDiCube is set to rebrand as Renovaro.AI, and together, the entities are looking to hasten diagnosis processes, improve the efficacy of treatments, pioneer new therapies, and broaden the availability of vital technologies for cancer and other diseases.
Dybul highlighted to Proactive that while Renovaro is currently concentrated on pancreatic cancer research, plans are afoot to extend their focus to include other solid tumors that are typically associated with a short life expectancy. These will be part of the first human Phase I/IIa studies anticipated to commence by mid-2024. He not…...more